An interventional study of triptorelin and hCG in Infertility and at High Risk of OHSS, sponsored by Chenshiling. Status unknown at 1 site in China. Open to female participants aged Up to 40 Years. Per ClinicalTrials.gov, last updated 2013-12-27.
Sponsored by Chenshiling · Not applicable, Interventional, and Prevention
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk patients.
However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH) level post trigger with single injection of GnRH agonist, which might be related to the shorter duration and lower amount of LH induced by GnRH agonist.
Our aim is to study dual trigger with GnRH agonist and human chorionic gonadotropin (hCG) for preventing OHSS and maintaining clinical outcome in high risk patients who receive controlled ovarian stimulation in GnRH antagonist protocol.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's planned enrollment of 200 is above the median of 120 across 1,698 interventional studies indexed under Infertility.
Browse Infertility studies →Chenshiling is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients were triggered with 0.2mg triptorelin and 500 IU hCG
Drug: triptorelin · Drug: hCG
Patients were triggered with 0.2mg triptorelin and 1000 IU hCG
Drug: triptorelin · Drug: hCG
0.2 mg triptorelin, ih
Also known as: triptorelin: Diphereline
1000 IU hCG, im
500IU hCG, im
clinical pregnancy rate per transfer cycle
Time frame: 1month post embryo transfer
numbers of patients having OHSS
Time frame: 2 weeks post trigger with dual GnRHa
oocyte yield
Oocyte yield was defined as the ratio of the total number of collected oocytes to the number of follicles measuring ≥10 mm on the day of oocyte retrieval.
Time frame: oocyte retrieval day (34 to 38 hours post trigger with GnRHa and hCG)
Oocyte maturity
Oocyte maturity was defined as the ratio of metaphase II (MII) oocytes to the number of collected oocytes in the patients undergoing with intracytoplasmic sperm injection (ICSI).
Time frame: 24 hours post oocyte retrieval day
serum luteinizing hormone level 12 hours post trigger
Time frame: 12 hours post trigger
serum hCG level 12 hours post trigger
Time frame: 12 hours post trigger
fertilization rate
Fertilization rate was defined as the ratio of normal fertilized oocytes (2PNs) to the number of oocytes used for fertilization (i.e. the denominator in IVF in calculating fertilization rate is all oocytes recovered, but in ICSI it is calculated using only the number of MII oocytes).
Time frame: 48 hours post IVF/ICSI
implantation rate
Time frame: 1 month post embryo transfer
This study is status unknown, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chenshiling